Superior Neutralizing Antibody Levels Against Omicron BF.7 and BA.2.75 of The Company’s Two Component Recombinant COVID-19 Vaccine Vaccine ReCOV Compared to International Mainstream mRNA Vaccine

TAIZHOU, China, Dec. 26, 2022 /PRNewswire/ — Jiangsu Recbio Technology Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant two-component COVID-19 vaccine ReCOV in The Philippines. This clinical study aims to compare the immunogenicity and safety profile of ReCOV and Pfizer’s mRNA vaccine COMIRNATY®as booster vaccination among subjects who have completed primary vaccination of inactivated vaccines. The results of sequential vaccination of ReCOV showed significantly higher levels of neutralizing antibodies against Omicron BF.7 (and BA.2.75 respectively) than those of the Pfizer mRNA vaccine group (with statistically significant differences).

The current main strain is in Beijing Omicron BF.7. Omicron BF.7 is a variant of Omicron. It has a stronger immune escape capability, faster infection rate and stronger concealment. Therefore, vaccination of vaccines with better efficacy is key to ending the epidemic.

1. The mRNA vaccine has statistically higher levels of neutralizing antibody titer against Omicron.BF.7 than the ReCOV group. The seroconversion rate of neutralizing antibodies against Omicron BF.7 in the ReCOV and mRNA vaccination groups was 91.1% and 88.4% respectively 14 days after booster vaccine. The SCR of Omicron BF.7 in the ReCOV and mRNA vaccination groups was higher than the mRNA vaccin group’s. At the same time, the geometric mean titers (GMT) of neutralizing antibodies in the ReCOV group and the mRNA vaccine group were 6,549.1 and 4,529.6, respectively, and the GMT in the ReCOV group was significantly higher than that in the mRNA vaccine group (P value < 0.001). The ReCOV group induced a 30.8-fold increase in neutralizing antibodies compared to the baseline. This was significantly greater than the 22.7 times for the mRNA vaccination. The ReCOV group had a neutralizing antibody against Omicron BF.7 that was 2.5 times lower than the original strain. This shows a strong cross-neutralization effect.

2. The mRNA vaccine had a statistically superior level of neutralizing antibody levels against OmicronBA.2.75 After 14 days of booster vaccination, the SCRs of neutralizing antibodies against OmicronBA.2.75 from the ReCOV (and the mRNAvaccine) groups were 92.1%, 88.4% and respectively higher than those of the mRNAvaccine group. The neutralizing antibody GMT for the ReCOV and mRNA vaccination groups was 6,268.3 and 4,676.3 respectively. (P value = 0.03). ReCOV also induced 27.3 times more neutralizing antibodies than the baseline. This is significantly higher than the 21.5 times that were effected by the mRNA vaccination. ReCOV showed a remarkable cross-neutralization effect, with the Omicron BA.2.75 neutralizing antibody only 2.6 times lower in the ReCOV.

The Company is developing ReCOV, a recombinant COVID-19 vaccination. It uses its technology platforms which include novel adjuvants, protein engineering, immunological evaluation platforms and adjuvants. It offers a number of advantages including a positive neutralizing effect and immuno persistence, an overall positive safety profile and potential growth in scale, low production costs, preparation stability and the ability to be stored at room temperature. The Company has completed construction of ReCOV manufacturing facilities and prepared for commercial production. It has also obtained the required vaccine production license from the regulatory authorities. ChinaThe product is ready for commercialization China.

Recbio

Recbio was established in 2012 and is an innovative vaccine business. Recbio was founded in 2012 with the vision to “Become the Leader of Innovative Vaccines in the Future”. Recbio’s mission is “Protect Human Health using Best-in-Class Vaccines”. Recbio has three major technology platforms, including a novel adjuvants platform as well as a protein engineering platform, immunological assessment platform, and mRNA vaccination platform. Recbio has a high-value vaccine portfolio consisted of HPV vaccine candidates, COVID-19 vaccine candidates, shingles vaccine candidates, influenza vaccine candidates, adults TB vaccine candidates etc. The core management team is more than 20-years old and has extensive experience in the commercialization and development of new vaccines. Please visit www.vaccines.org for more information. https://www.recbio.cn/.

Forward-looking statements

This presentation may include projections, estimates and forecasts. These statements can be identified using forward-looking terminology like “may”,’should”, ‘anticipate”, ‘project”, estimate”, seek”, intend”, ‘potential”, & “reasonably feasible” (collectively, “forward looking statements”). Forward-looking statements do not provide a reliable indicator for future performance as they could involve significant implied or stated assumptions or subjective judgments that may or may not be accurate, complete, or correct. Forward-looking statements do not guarantee that any of the things stated in them will become a reality, or that they will be realized or accurate. The Group cannot guarantee that the assumptions and judgments made may be correct, incorrect or incomplete. There are also known and unknown risks, uncertainties and other important players, many of whom are beyond its control. It is not possible to guarantee that the Group will be able to market or develop its core products and other pipeline candidates. Due to a number of factors, including general market conditions and regulatory changes, geopolitical tensions and data limitations and modifications, actual achievements, performance and other conditions could be materially different from the ones implied and/or reflected by any forward-looking statement. Any such forward-looking statements are based on the beliefs, expectations and opinions of the Group at the date the statements are made, and the Group does not assume, and hereby disclaims, any obligation or duty to update, revise or supplement them if circumstances or management’s beliefs,  expectations or opinions should change. Forward-looking statements should not be relied upon and you are cautioned against doing so. No representations or warranties, expressed or implied, are given by  or on behalf of the Group as to the achievement or reasonableness of any projections, estimates, forecasts, targets, commitments, prospects or returns contained herein.

Please refer the Announcements published by The Stock Exchange of Hong Kong Limited to see the details.www.hkexnew.hk) or of the Company (www.recbio.cn) for further details. If this Presentation is inconsistent with the announcements, then the announcements shall prevail.

Similar Links:
https://www.recbio.cn/

SOURCE Jiangsu Recbio Technology Co. Ltd.